RARE Daily

FDA Approves Regeneron’s RNA-Based Treatment for Myasthenia Gravis

November 20, 2026

Rare Daily Staff

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals’ Livsayis, a treatment given by injection every three months for certain adults with generalized myasthenia gravis, a rare autoimmune disease that can impair movement, swallowing and breathing.

Myasthenia gravis disrupts communication between nerves and muscles, causing weakness that can fluctuate unpredictably. In its generalized form, the disease can affect muscles throughout the body, making everyday activities such as speaking, eating and walking difficult. Severe episodes can weaken breathing muscles enough to require hospitalization.

In patients with antibodies against the acetylcholine receptor, the immune system activates a chain of proteins known as the complement system, contributing to damage where nerves connect with muscles. Livsayis breaks down the molecular instructions used to make one of those proteins, called C5, reducing its levels in the bloodstream.

Livsayis is the first approved treatment for the disease to use small interfering RNA, a technology that reduces production of a specific protein.

The approval covers adults who test positive for antibodies against the acetylcholine receptor. This antibody-positive form is the most common form of the disease. According to Regeneron, Livsayis is the only FDA-approved treatment for generalized myasthenia gravis administered under the skin four times a year.

The drug carries a boxed warning for serious, potentially fatal meningococcal infections and will be available only through a restricted safety program.

“For people living with gMG, every day can be unpredictable, due to fluctuating muscle weakness and fatigue,” said Tuan Vu, a University of South Florida neurologist and a global principal investigator of the trial supporting approval, in Regeneron’s announcement. “They may also experience severe exacerbations that can be life-threatening.”

The FDA’s decision was based on results from the ongoing Phase 3 NIMBLE trial, which randomly assigned participants to Livsayis, placebo or other treatment regimens. Participants could continue background immune-suppressing medicines at the investigator’s discretion.

After 24 weeks, patients receiving Livsayis improved by an average of 4.5 points on a 24-point scale measuring how the disease affects daily activities, compared with 2.2 points among those receiving placebo. The difference was statistically significant. The assessment covers functions including talking, chewing, swallowing, breathing and mobility, with lower scores indicating less severe symptoms.

About 77 percent of Livsayis recipients achieved at least a three-point improvement on that scale, compared with about 44 percent of placebo recipients. A separate clinician-administered assessment of muscle function also favored Livsayis.

Regeneron said improvements appeared as early as two weeks after treatment began and were maintained through the three-month dosing intervals during the 24-week assessment period.

Because C5 also helps the body fight infection, reducing its activity carries risks. Livsayis can increase susceptibility to meningococcal infections, which can rapidly become life-threatening even in vaccinated patients.

Patients generally must complete meningococcal vaccination at least two weeks before their first dose. Those who need to start immediately without being up to date on vaccination must receive antibiotics as well as the required vaccines. Prescribers must enroll in the drug’s Risk Evaluation and Mitigation Strategy, or REMS, program and counsel patients about infection risks.

The most common side effects reported more frequently with Livsayis than with placebo included injection-site reactions, viral infections and urinary tract infections. The drug may also increase the risk of other serious bacterial infections.

Livsayis is Regeneron’s first approved neurological medicine and its first approved small interfering RNA therapy. The company holds worldwide development, manufacturing and commercialization rights through a licensing agreement with Alnylam Pharmaceuticals.

The treatment is also under review in the European Union, where the company expects a decision in the second half of 2027.

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube